Results 211 to 220 of about 1,213,965 (250)

Multivariate linear regression to predict association of non‐invasive arterial stiffness with cardiovascular events

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1141-1150, April 2025.
Abstract Background Arterial stiffness is a crucial factor in determining an increase in systolic blood pressure and pulse pressure and can also predict the development of cardiovascular disease (CVD). The purpose of this study was to examine the relationship between arterial stiffness and future CVD.
Susan Darroudi   +10 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia   +2 more
wiley   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen   +7 more
wiley   +1 more source

Causal correlations between inflammatory proteins and heart failure: A two‐sample Mendelian randomization analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1374-1385, April 2025.
Abstract Aims Inflammation plays a critical role in both the development and progression of heart failure (HF), which is a leading cause of morbidity and mortality worldwide. However, the causality between specific inflammation‐related proteins and HF risk remains unclear.
Xian‐Guan Zhu   +9 more
wiley   +1 more source

The effect of anti‐seizure medications on exposure to statins: A systematic review and meta‐analysis

open access: yesEpileptic Disorders, EarlyView.
Abstract Objectives Antiseizure medications (ASMs) can reduce the efficacy of statin treatment, partly due to reduction in statin concentrations. In this systematic review and network meta‐analysis (NMA), we compared the effects of ASMs and the prototypical enzyme inducer rifampin on statin exposure.
Sharon Valiyev Huino   +5 more
wiley   +1 more source

Cardiovascular events and mortality in adults with late onset seizures: Focus on enzyme‐modulating antiseizure medications

open access: yesEpilepsia, EarlyView.
Abstract Objective Using a Dutch insurance claims registry, we examine whether people with epilepsy have an increased risk of major ischemic cardiovascular events or death compared to people without epilepsy. We also assess whether this risk differs between users of enzyme‐modulating and non‐enzyme‐modulating antiseizure medications (ASMs).
Paola Vassallo   +4 more
wiley   +1 more source

ASGR1 Deficiency Inhibits Atherosclerosis in Western Diet-Fed <i>ApoE<sup>-/-</sup></i> Mice by Regulating Lipoprotein Metabolism and Promoting Cholesterol Efflux. [PDF]

open access: yesArterioscler Thromb Vasc Biol
Zhang Y   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy